$KROS

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.